Anxiety and depression: Optimizing treatments

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 2, Issue 3, 2000, Pages 71-79

  Ballenger, James C ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 21244496258     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v02n0301     Document Type: Article

References (71)

1. Rice DP, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry 1998; 173 (suppl 34):4-9
2. Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anx- iety disorders in the 1990s. J Clin Psychiatry 1999;60:427-435
3. Souetre E, Lozet H, Cimarosti I, et al. Cost of anxiety disorders: impact of comorbidity. J Psychosom Res 1994;38(suppl 1):151-160
4. Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry 1996;168(suppl 30):17-30
5. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
7. American Psychiatric Association. Anxiety algorithm. In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Primary Care Version. Washington, DC: American Psychiatric Association; 1995:47-63
8. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. NEnglJMed 1993;328:1398-1405
9. Burke WJ, Folks DG, McNeilly DP. Effective use of anxiolytics in older adults. Clin GeriatrMed 1998; 14:47-65
10. Goldberg RJ. Diagnostic dilemmas presented by patients with anxiety and depression. Am J Med 1995;98:278-284
11. Ballenger JC, Burrows GD, DuPont RLJ, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, 1: efficacy in shortterm treatment. Arch Gen Psychiatry 1988;45:413-422
12. Sussman N. The uses of buspirone in psychiatry. J Clin Psychiatry Monograph 1994;12(1):3-19
13. Ballenger J. Treatment of panic disorder with serotonin reuptake inhibitors (SSRIs). In: den Boer JA, Montgomery SA, eds. SSRIs in Depression and Anxiety. Chichester, NY: JohnWiley & Sons; 1998:115-134
14. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995; 152:1368-1371
15. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.JAMA 1998;280:708-713
16. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998;155:36-42
17. Baljenger JC. Current treatments of the anxiety disorders in adults. Biol Psychiatry 1999;46:1579-1594
18. Fawcell J, Barkin RL. A meta-analysis of eight randomized, double-blind, control ep clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998;59:127
19. Stinime KGL, Donheidede JA, Stahl SM. Mirtazapine: an antidepressant with noradrenefgic. and serotonergic effects. Pharmacotherapy 1997; 17:10-21
20. Dopheide JA, Stilruner DD. Focus on nefazodone: a serotonergic drug for major depression: Formulary 1995;30:205-210, 212
21. Rickels K, Pollack MH, Sheehtn-bv, -et al. Efficacy of extended-release venlafaxine in nondepressed outpatigats iiyith generalized anxiety disorder. Am J Psychiatry 2000; 157:968-97
22. Davidson JRT, DuPont RL, Hedges D.et al\Efficacy, safety, and tolerability of venlafaxine extended release and buspiijohe in outpatients with generalized anxiety disorder. J Clin Psychiatry 1960:528-535
23. Haskins JT, Rudolph R, Aguiar L, et al. VentafaxinieXXR is effective for the short- and long-term treatment of generalzed anxiety disorder [poster]. Presented at the 11th World Congress of Psychiatry; Aug 6-11, 1999; Hamburg, Germany 4.
24. Hackett D, Desmet A, Saunas EO. Dose-response efficacy of long-term treatment of venlafaxine extended-release in generalized anxiety disorder [abstract]. Eur Neuropsychopharmacol 1999;9(suppl 5):S315
25. Haskins JT, Rudolph R, Aguiar L, et al, for the Venlafaxine XR 218 Study Group. Venlafaxine XR is an efficacious short- and long-term treatment for generalized anxiety disorder. Presented at the 11 th annual congress of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France
26. Hackett D, Desmet A, Saunas EO. Dose-response efficacy of venlafaxine XR in GAD [poster]. Presented at the 11th World Congress of Psychiatry; Aug 6-11, 1999; Hamburg, Germany
27. Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995;31: 767-771
28. Geracioti TD Jr. Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 1995;56:408-410
29. Rauch SL, OSullivan RL, Jenike MA. Open treatment of obsessivecompulsive disorder with venlafaxine: a series of ten cases [letter]. J Clin Psychopharmacol 1996;16:81-84
30. Khan A, Upton GV, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol 1998;18:19-25
31. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998;47:55-62
32. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16(3, suppl 2):37S-53S
33. Council on Scientific Affairs, American Medical Association. The etiologic featiftes-of depression in adults. Arch Earn Med 1993;2:76-84
34. De WesterJN. Recognizing and treating the patient with somatic manifestations of depression? J Earn Pract 1996;43(suppl 6):S3-S15
35. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addictive disorders service system: Epidemiologie Catchment Area prospective 1-year prevalence rate of disorders and services. Arch Gen Psychiatry 1993;50:85-94
36. Ormel J, VonKorff M, Ustun TB et al. Common mental disorders and disability across cultures: results from the WHO Collaborative Study on Psychological Problems in General Care. JAMA 1994;272: 1741-1748
37. Blazer DG, Kessler RC, McGonagle KA, et al. The prevalence and distribution of major depression in a national comjnuflitjl sample: the National Comorbidity Survey. Am J Psychiatry 1994;15:l
38. Cross-National Collaborative Group. The major depression: cross-national comparisons. JAMA 1992;258:309-131
39. Dunner DL. Therapeutic considerations in treating depression in the elderly. J Clin Psychiatry 1994;55( 12, suppl):48-58
40. Montano CB. Recognition and treatment of depressiort-in a prirfiafy care setting. J Clin Psychiatry 1994;55(12, suppl): 18-34
41. American Psychiatric Association. Depressed mood Diagnostic and Statistical Manual of Mental Disorders, FoufftïEditiorg Primary Care Version. Washington, DC: American Psychiatric Associa- tion; 1995:35-45
42. Cohen LJ. Rational drug use in the treatment of depression. PharmacQ/i therapy 1997;17:45-61
43. Simon G, Ormel J, VonKorff M, et al. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 1995; 152:352-357
44. Frazer A. Antidepressant drugs. Depression 1994;2:1-19
45. Wells KB, Katon W Rogers B, et al. Use of minor tranquilizers and antidepressant medications by depressed outpatients: results from the Medical Outcomes Study. Am J Psychiatry 1994;151:694-700
46. Hirschfeld RMA. Guidelines for the long-term treatment of depression. J Clin Psychiatry 1994;55(12, suppl):61-69
47. Frank E, Kupfer DJ, Perel JM, et al. Comparison of full-dose versus halfdose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993;27:139-145
48. Noble S, Benfield P. Citalopram: a review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs 1997; 8:410-431
49. Central nervous system drugs. In: Drug Facts and Comparisons, 1999 ed. St. Louis, Mo: Facts and Comparisons; 1998:1603
50. Danish University Antidepressant Group. Citalopram: clinical effect pro-file in comparison with clomipramine: a controlled multicenter study. Psychopharmacology 1986;90:131-138
51. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18:289-299
52. Kelsey JE. Dose-response relationship with venlafaxine. J Clin Psychopharmacol 1996;16(suppl 2):21S-28S
53. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994;55(9, suppl A):62-70
54. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-458
55. Thase ME. Antidepressant options: venlafaxine in perspective. J Clin Psychopharmacol 1996;16(3, suppl 2):10S-20S
56. Jefferson JW. Drug interactions: friend or foe? J Clin Psychiatry 1998;59 (suppl 4):37-4T7
57. Wells BG, Mandos EA. Depressive disorders. In: DiPiro JT, Talbert RE, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. Stamford, Conn: Appleton & Eange; 1997:1395-1417
58. Brown C, Schulberg HC, Madonia MJ, et al. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry 1996;153:1293-1300
59. Schapira K, Roth M, Kerr TA, et al. The prognosis of affective disorders: the differentiation of anxiety states from depressive illnesses. Br J Psychiatry 1972;121:175-181
60. Kessler RC, DuPont RE, Berglund P, et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999;156:1915-1923
61. Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety 1996;4:160-168
62. Kuzel RJ. Treating comorbid depression and anxiety. J Earn Pract 1996;43 (6, suppl):S45-S53
63. Keller MB, Hanks DE. Anxiety symptom relief in depression treatment outcomes. J Clin Psychiatry 1995;56(suppl 6):22-29
64. Eepola UM, Wade AG, Eeinonen EV, et al. A controlled prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998;59:528-534
65. Kojjsnen H, Eepola U, Eeinonen E, et al. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand 1997,96:343-346
66. 66: Pollack fptE.Worthington JJ III, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull S96;32:667-670
67. Hedges.-D;-4, Rennljerr FW, Strong RE, et al. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol Bull 1996;32:671-676.
68. Greist JH, Jeffer Son JW Obak KA, et al. Efficacy and tolerability of serotonin transport inhibito obsessive-compulsive disorder: a metaanalysis. Arch Gen Psychiatry 995;52;53-60
69. Jefferson JW. Antidepressants in panisfajsorder. J Clin Psychiatry 1997;58 (suppl 2):20-25
70. Quitkin FM, McGrath PJ, Stewart JW, Chronological milestones to guide drug change: when should clinicians.switch antidepressants? Arch Gen Psychiatry 1996;53:785-792
71. Ballenger JC. Clinical evaluation of venlafaxine.jj ClinPsychopharmacol 1996;16(suppl 2):29S-36S